Literature DB >> 27493238

Preexisting Antibody-Dependent Cellular Cytotoxicity-Activating Antibody Responses Are Stable Longitudinally and Cross-reactive Responses Are Not Boosted by Recent Influenza Exposure.

Sophie A Valkenburg1, Yanyu Zhang2, Ka Y Chan2, Kathy Leung2, Joseph T Wu2, Leo L M Poon2.   

Abstract

Cross-reactive influenza virus-specific antibody-dependent cellular cytotoxicity (ADCC)-activating antibodies are readily detected in healthy adults. However, little is known about the kinetics of these ADCC responses. We used retrospective serial blood samples from healthy donors to investigate this topic. All donors had ADCC responses against 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09) and avian influenza A(H7N9) virus hemagglutinins (HAs) despite being seronegative for these viruses in standard hemagglutination inhibition and microneutralization serological assays. A(H1N1)pdm09 exposure did not boost ADCC responses specific for H7 HA antigens. H7 HA ADCC responses were variable longitudinally within donors, suggesting that these cross-reactive antibodies are unstable. We found no correlation between ADCC responses to the H7 HA and either influenza virus-specific immunoglobulin G1 concentration or age.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  ADCC; NK cells; antibody; influenza

Mesh:

Substances:

Year:  2016        PMID: 27493238      PMCID: PMC5034955          DOI: 10.1093/infdis/jiw346

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Broadly neutralizing antiviral antibodies.

Authors:  Davide Corti; Antonio Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2013-01-16       Impact factor: 28.527

2.  Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity in intravenous immunoglobulin as a potential therapeutic against emerging influenza viruses.

Authors:  Sinthujan Jegaskanda; Kirsten Vandenberg; Karen L Laurie; Liyen Loh; Marit Kramski; Wendy R Winnall; Katherine Kedzierska; Steven Rockman; Stephen J Kent
Journal:  J Infect Dis       Date:  2014-06-10       Impact factor: 5.226

3.  Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus.

Authors:  Mark W LaMere; Ho-Tak Lam; Amy Moquin; Laura Haynes; Frances E Lund; Troy D Randall; Denise A Kaminski
Journal:  J Immunol       Date:  2011-02-25       Impact factor: 5.422

4.  High Antibody-Dependent Cellular Cytotoxicity Antibody Titers to H5N1 and H7N9 Avian Influenza A Viruses in Healthy US Adults and Older Children.

Authors:  Masanori Terajima; Mary Dawn T Co; John Cruz; Francis A Ennis
Journal:  J Infect Dis       Date:  2015-03-20       Impact factor: 5.226

5.  Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Authors:  Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Immunol       Date:  2013-01-14       Impact factor: 5.422

6.  A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

Authors:  Damian M Carragher; Denise A Kaminski; Amy Moquin; Louise Hartson; Troy D Randall
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

7.  Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques.

Authors:  Sinthujan Jegaskanda; Thakshila H Amarasena; Karen L Laurie; Hyon-Xhi Tan; Jeff Butler; Matthew S Parsons; Sheilajen Alcantara; Janka Petravic; Miles P Davenport; Aeron C Hurt; Patrick C Reading; Stephen J Kent
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

8.  Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1.

Authors:  Sinthujan Jegaskanda; Karen L Laurie; Thakshila H Amarasena; Wendy R Winnall; Marit Kramski; Robert De Rose; Ian G Barr; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Infect Dis       Date:  2013-06-28       Impact factor: 5.226

9.  Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques.

Authors:  Sinthujan Jegaskanda; Jason T Weinfurter; Thomas C Friedrich; Stephen J Kent
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

10.  Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity.

Authors:  Brian J Laidlaw; Vilma Decman; Mohammed-Alkhatim A Ali; Michael C Abt; Amaya I Wolf; Laurel A Monticelli; Krystyna Mozdzanowska; Jill M Angelosanto; David Artis; Jan Erikson; E John Wherry
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

  10 in total
  4 in total

1.  Cross-reactive antibody-dependent cellular cytotoxicity antibodies are increased by recent infection in a household study of influenza transmission.

Authors:  Sophie A Valkenburg; Vicky J Fang; Nancy Hl Leung; Daniel Kw Chu; Dennis Km Ip; Ranawaka Apm Perera; Yizhuo Wang; Athena Py Li; Js Malik Peiris; Benjamin J Cowling; Leo Lm Poon
Journal:  Clin Transl Immunology       Date:  2019-11-20

2.  Vaccination with ADCC activating HA peptide epitopes provides partial protection from influenza infection.

Authors:  Niloufar Kavian; Asmaa Hachim; Leo L M Poon; Sophie A Valkenburg
Journal:  Vaccine       Date:  2020-07-25       Impact factor: 3.641

Review 3.  The Hurdles From Bench to Bedside in the Realization and Implementation of a Universal Influenza Vaccine.

Authors:  Sophie A Valkenburg; Nancy H L Leung; Maireid B Bull; Li-Meng Yan; Athena P Y Li; Leo L M Poon; Benjamin J Cowling
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

4.  The Potential Role of Fc-Receptor Functions in the Development of a Universal Influenza Vaccine.

Authors:  Sinthujan Jegaskanda
Journal:  Vaccines (Basel)       Date:  2018-05-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.